Merck & Co. Inc. may have beat the odds and breathed new life into the CETP inhibitor class with the demonstration of a cardiovascular outcomes advantage for its anacetrapib in the 30,000-patient REVEAL trial, but the company seems uncertain of its next steps.
Merck has said merely that it planned to review the REVEAL results of the trial with external experts, and would "consider whether to file new drug
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?